Successful administration of glecaprevir/pibrentasvir via percutaneous endoscopic gastrostomy in a pediatric patient with chronic hepatitis C and spinal muscular atrophy receiving risdiplam.

Glecaprevir/Pibrentasvir (GLE/PIB) is an interferon-free direct-acting antiviral (DAA) regimen indicated for the treatment of chronic hepatitis C virus (HCV) infection. However, data on the pharmacokinetics and stability of crushed or split tablets are lacking, complicating administration in patients with dysphagia requiring percutaneous endoscopic gastrostomy (PEG). Additionally, no published studies have evaluated the safety and efficacy of DAAs in combination with Risdiplam, the first oral therapy developed for spinal muscular atrophy (SMA). We report a case of a 14-year-old dysphagic patient with SMA, receiving Risdiplam, who was successfully treated with crushed GLE/PIB administrated via PEG. The patient achieved a sustained virologic response (SVR) 12 weeks after the end of therapy, without significant adverse effects, and no drug interactions were observed during the course of treatment.